Table 8.
Clinical characteristics of all patients: pre-treatment, end of initial study, and latest follow-up.
| Characteristic | Pre-treatment | End of initial study | Latest follow-up |
|---|---|---|---|
| Functional Class | |||
| I | 4 (14.3) | 5 (17.9) | 2 (7.2) |
| II | 14 (50) | 8 (28.5) | 10 (35.7) |
| III | 9 (32.1) | 9 (32.1) | 7 (25) |
| IV | 0 (0) | 1 (3.6) | 0 (0) |
| Not Done | 1 (3.6) | 5 (17.9) | 9 (32.1) |
| 6MWD (m) | 517 (441–573) | 514 (428–547) | 582 (555–600) |
| n (%) | 25 (89.3) | 21 (75) | 13 (46.4) |
| Time between test and initiation (months) | 1.3 (1.0–3.4) | 2 (1.5–3.0) | 12 (5–14.9 |
| BNP (pg/mL) | 29.3 (15.0–80) | 21 (11–56) | 19 (16–45.3) |
| n (%) | 26 (92.9) | 19 (67.8) | 15 (53.5) |
| Time between test and initiation (months) | 2.0 (0.5–3.4) | 2 (1.5–6.0) | 6 (4–14.9) |
| NT-pro BNP (pg/mL) | 156 (125–183) | 274 (270–278) | 133 (108–243) |
| n (%) | 5 (17.9) | 4 (14.2) | 6 (21.4) |
| Time between test and initiation (months) | 1.3 (1.3–2.3) | 5.2 (3.4–69.9) | 16.1 (12.6–19.1) |
| Echocardiographic measures | |||
| TR gradient (mmHg) | 62 (50–79) | 74 (49–93) | 73.5 (51–92) |
| n (%) | 22 (78.5) | 19 (67.8) | 14 (50) |
| Time between test and initiation (months) | 2.2 (1.0–4.0) | 2 (1.5–3.0) | 9.3 (5–14.9) |
| TAPSE (cm) | 2.0 (1.8–2.2) | 2.0 (1.6–2.4) | 1.9 (1.6–2.16) |
| n (%) | 11 (39.3) | 12 (42.8) | 11 (39.2) |
| Time between test and initiation (months) | 1.3 (1.2–3.0) | 2.3 (1–6.9) | 12.6 (8.6–19.1) |
| Invasive hemodynamic measures | |||
| mRAP (mmHg) | 7.0 (6.0–9.5) | 8 (7–8) | 7 (4–10) |
| n (%) | 24 (85.7) | 6 (21.4) | 2 (7.1) |
| Time between test and initiation (months) | 12.5 (4.7–23.2) | 6.4 (1.7–20) | 17.6 (12.1–23.1) |
| mPAP (mmHg) | 49 (39–60) | 36.5 (35–75) | 69.5 (65–75) |
| n (%) | 24 (85.7) | 6 (21.4) | 2 (7.1) |
| Time between test and initiation (months) | 12.5 (4.7–23.2) | 6.4 (1.7–20) | 17.6 (12.1–23.1) |
| Mean PAWP (mmHg) | 11 (8–12) | 10 (7–11) | 9 (5–13) |
| n (%) | 24 (85.7) | 5 (17.8) | 2 (7.1) |
| Time between test and initiation (months) | 12.5 (4.7–23.2) | 1.8 (1.7–11) | 17.6 (12.1–23.1) |
| Cardiac index (L/min/m2) | 3.5 (3.0–4.5) | 3.7 (3.0–4.4) | 3 (2.7–3.3) |
| n (%) | 22 (78.6) | 6 (21.4) | 2 (7.1) |
| Time between test and initiation (months) | 12.0 (3.3–24.6) | 6.4 (1.7–20) | 17.6 (12.1–23.1) |
| PVRI (Wood units*m2) | 9.7 (5.9–14.9) | 10.2 (4.8–17.3) | 21.6 (14.9–28.2) |
| n (%) | 23 (82.1) | 6 (21.4) | 2 (7.1) |
| Time between test and initiation (months) | 12.0 (3.3–24.6) | 6.4 (1.7–20.0) | 17.6 (12.1–23.1) |
Values are given as n (%) or median (IQR).
Note time between test and initiation is months before start for the “Pre” state and after start for the post and latest states.
BNP, B-type natriuretic peptide; NT-pro BNP, N-terminal pro-B-type natriuretic peptide; TR, tricuspid regurgitation; TAPSE, tricuspid annular plane systolic excursion; mRAP, mean right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PVRI, pulmonary vascular resistance index.